STOCK TITAN
  1. Home
  2. Sec-filings
  3. DTIL
  4. [Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity

Precision Biosciences (NASDAQ: DTIL) director’s 21,000 RSUs vest into shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Germano Geno J reported acquisition or exercise transactions in this Form 4 filing.

PRECISION BIOSCIENCES INC director Germano Geno J reported a routine equity compensation event. On May 20, 2026, 21,000 Restricted Stock Units vested and were settled into 21,000 shares of Common Stock at a price of $0.00 per share. Following this vesting, he directly holds 44,883 shares of Common Stock. The RSUs were originally granted on June 3, 2025 and were scheduled to vest on the earlier of June 3, 2026 or the day immediately before the company’s next annual stockholders’ meeting, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Germano Geno J
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 21,000 $0.00 --
Exercise Common Stock 21,000 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 44,883 shares (Direct, null)
Footnotes (1)
  1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
RSUs vested 21,000 units Restricted Stock Units vested on May 20, 2026
Shares issued from RSUs 21,000 shares Common Stock received upon RSU vesting
Post-transaction holdings 44,883 shares Common Stock held directly after transaction
RSU grant date June 3, 2025 Original grant of RSUs to director
Vesting trigger Earlier of June 3, 2026 or pre-annual meeting RSU vesting condition tied to time and service
Exercise price $0.00 per share Conversion of RSUs into Common Stock
Restricted Stock Units financial
"Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vesting financial
"Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
Common Stock financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
annual meeting of stockholders financial
"…the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date…"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Germano Geno J
(Last)(First)(Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E. PETTIGREW ST., SUITE A-100
(Street)
DURHAM NORTH CAROLINA 27701
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/20/2026M21,000(1)A(2)44,883D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(2)05/20/2026M21,000 (3) (3)Common Stock21,000$00D
Explanation of Responses:
1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Remarks:
/s/ Dario Scimeca Attorney-in-Fact for Geno J. Germano05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Precision Biosciences (DTIL) disclose for Germano Geno J?

Precision Biosciences disclosed that director Germano Geno J had 21,000 Restricted Stock Units vest into 21,000 shares of Common Stock on May 20, 2026. This was a compensation-related equity vesting, not an open-market stock purchase or sale.

How many Precision Biosciences (DTIL) shares does Germano Geno J hold after this Form 4?

After the RSU vesting, Germano Geno J directly holds 44,883 shares of Precision Biosciences Common Stock. This total reflects the addition of 21,000 newly issued shares from vested RSUs and indicates his post-transaction equity position reported in the filing.

Was the Precision Biosciences (DTIL) Form 4 an open-market trade or an RSU vesting?

The Form 4 reflects an RSU vesting, not an open-market trade. 21,000 Restricted Stock Units converted into 21,000 shares of Common Stock at $0.00 per share, consistent with equity compensation rather than a discretionary market purchase or sale.

What were the vesting terms for Germano Geno J’s RSUs at Precision Biosciences (DTIL)?

The RSUs were granted on June 3, 2025 and vested on the earlier of June 3, 2026 or the day immediately prior to the company’s next annual stockholders’ meeting. Vesting was conditioned on Germano Geno J’s continued service through the applicable vesting date.

How many Restricted Stock Units vested for Germano Geno J at Precision Biosciences (DTIL)?

A total of 21,000 Restricted Stock Units vested for Germano Geno J. Each RSU represented a contingent right to receive one share of Precision Biosciences Common Stock, resulting in 21,000 new shares issued to him upon vesting.